Navimeso® Preparation

30 days left
Minimum target
Navimeso® Preparation 0 Navimeso® Preparation 1
Navimeso® Preparation 1 Navimeso® Preparation 1

Investor Benefits and Loan Security

Schaeffer Nutraceuticals is an established German pharmaceutical company that specializes in the development of next-generation supplements using industry-leading research. At the moment, they are looking to generate capital to boost their research and development capabilities, especially now that they are looking to expand their current lineup of products. By partnering with TFGcrowd, they are looking to raise a minimum target of 50’000€, with a total target of 100’000€, and are willing to reward potential investors with a rate of 17.7%, to be paid out over the loan term of 6 months.

The following pledges secure the loan:

•    A pledge on PROTO GLOBAL GmbH

•    Personal guarantee of the Borrowers’ shareholders & CEO

•    Guarantee of the Borrower

The loan is offered with the BuyBack Guarantee: thus, if a borrower is late with the repayment of the loan, TFGcrowd will compensate the investors both the invested principal amount and interest, as well as pay the accrued interest after 60 days of delay.

Schaeffer Nutraceuticals is one of TFGcrowd’s most attractive projects yet. A favorable market conditions, and an ever-growing demand for their segment – you can’t go wrong with Vitaprotein as your next best investment.


Invest in Navimeso®

Schaeffer Nutraceuticals uses Nobel Prize-winning biotechnology research to produce diet supplements that tower above the rest  — Viproactive® brand of products. Their goal is simple — to enhance customers’ diets so they achieve the best energy levels, health, well-being and productivity possible.

Vitaprotein® is the product of over 20 years of molecular biological research spearheaded by Dr. Günter Blobel. Blobel is the esteemed German scientist and Nobel Prize awardee who developed Signal Theory, a remarkable discovery that singlehandedly revolutionized our modern understanding of how proteins are transported and assimilated throughout the body.

Navimeso® preparation is based on the studies of prof. Günter Blobel, who developed the amino acid signal theory. For his re-search, prof. Blobel received the 1999 Nobel Prize.

The production process of the unique VITAPROTEIN protein carrier, which uses the signal sequences of amino acids, was developed in Germany and the technological process was patented at the German Patent Office.

The formula of the NAVIMESO® preparation, combining active ingredients essential for the proper functioning of the skin with the unique VITAPROTEIN® carrier protein, facilitates skin assimilation and selectively directs the active complex to the target location in the body.
It's selectivity and a high concentration of active ingredients necessary for the proper functioning of the skin comprises the basic advantage of the preparation, which perfectly complements aesthetic medicine treatments, improving their effects, as well as sets new standards in anti-aging medicine.

Schaeffer Nutraceuticals is committed to providing customers with the world’s best diet supplements, delivered to where they are needed in the body in the fastest and most efficient way possible.

Following the success of their campaigns, Schaeffer Nutraceuticals decided to join hands with TFGcrowd once again to help them fund the next phase.


Market Outlook

Germany has several advantages for pharmaceutical companies, such as its market size, a robust legal framework for approval and reimbursement, as well as the quality and cost-effectiveness of its clinical research. In 2015, the global pharmaceutical market was 1.07 trillion USD. The US has the largest market with 433 billion USD, second is China with 115 billion USD, third is Japan with 81 billion USD, and Germany has the world’s fourth largest market with 43 billion USD. The German market is Europe’s largest market. Germany ranks fourth in the world as a location for conducting clinical trials. It has a global market share of 6.7% for all clinical studies, following the US (44%), China (9.8%) and Canada (7.2%).

More recent data for both the pharmaceutical market reflect conditions that bode well for companies like Schaeffer Nutraceuticals. The influx of new technologies have also expanded the existing distribution channels for nutraceutical goods, for example, an online pharmacy sales have grown in 2-digit rates in 2016, which made up 12% of the German OTC drug market at the time. The German pharmaceutical industry is also expected to grow from its 52.9 billion EUR benchmark in 2016 to 67.2 billion by 2021 at a CAGR of 4.9%

The same could be said about one of Germany’s fastest-growing segments under its pharmaceutical industry, the nutrition and supplements market. Growing health consciousness among the local populace has generated a more or less stable demand for nutritional supplements, generating US$31.7 billion in 2016 alone, and is expected to grow at a CAGR of 5.9% through 2025. Along with France and Italy, the German nutraceuticals industry made up over 40% of the total sales of Europe.

The primary drivers for demand locally appear to be adult consumers, which made up around 39.8% of the gross revenue from 2016. Taken together, these insights prove that companies like Schaeffer Nutraceuticals are in a favorable position to take advantage of the continued growth of both the pharmaceutical industry as a whole and the nutrition and supplements segment in particular. Coupled with Vitaprotein’s promising prospects as a product, an investment on Schaeffer Nutraceuticals today is almost guaranteed to turn in significant profit with the right level of investment.


Loan term
6 months
Interest rate
17.7% per year

Other Projects